FDA-cleared profile

VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

Spectrum Dynamics Medical, Ltd. · PET/SPECT/Nuclear Medicine · FDA-cleared (510(k))

Authorized purpose: VERITON CT 300/400 Series combines SPECT and CT for detection, localization, diagnosis, staging, restaging, organ-function assessment, therapy planning, guidance, and monitoring. Optional VERITAS.AI applies locked noise-reduction models to reconstructed SPECT images.

Clinical role
Hybrid SPECT/CT acquisition, reconstruction, quantification, diagnostic review, and therapy-planning or monitoring support.
Images and patients
PET/SPECT/Nuclear Medicine · Multi-region
Key limitation
Keep in mind: VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: VERITON CT 300/400 Series combines SPECT and CT for detection, localization, diagnosis, staging, restaging, organ-function assessment, therapy planning, guidance, and monitoring. Optional VERITAS.AI applies locked noise-reduction models to reconstructed SPECT images.
  • Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Multi-region Input: SPECT projection data and CT acquisition data; VERITAS.AI operates on reconstructed SPECT images.
  • Who uses it?Intended users: Qualified nuclear-medicine physicians, radiologists, technologists, and other trained healthcare professionals.
  • What does the software produce?Output: SPECT, CT, and fused images plus optional noise-reduced SPECT images and quantitative information.
  • What is its most important limitation?Key limitation: VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.

Clinical takeaway. Clinical role: VERITON CT 300/400 Series combines SPECT and CT for detection, localization, diagnosis, staging, restaging, organ-function assessment, therapy planning, guidance, and monitoring. Optional VERITAS.AI applies locked noise-reduction models to reconstructed SPECT images.

Evidence takeaway. Evidence from the reviewed source record: Exact-submission testing used a 30-patient held-out evaluation set and reported strong lesion-signal preservation with lower background variability after noise reduction. The evidence is manufacturer generated and must be supplemented with local quantitative and reader acceptance.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
VERITON CT 300/400 Series combines SPECT and CT for detection, localization, diagnosis, staging, restaging, organ-function assessment, therapy planning, guidance, and monitoring. Optional VERITAS.AI applies locked noise-reduction models to reconstructed SPECT images.
  • Exact FDA submission
  • Checked 2026-09-04

Added in P2 round17 from the exact FDA decision material; later product-family claims remain separate.

Workflow role
Hybrid SPECT/CT acquisition, reconstruction, quantification, diagnostic review, and therapy-planning or monitoring support.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
SPECT projection data and CT acquisition data; VERITAS.AI operates on reconstructed SPECT images.
  • Exact FDA submission
  • Checked 2026-09-03
Output and clinician action
SPECT, CT, and fused images plus optional noise-reduced SPECT images and quantitative information.
  • Exact FDA submission
  • Checked 2026-09-03
Care setting
Hospital and outpatient nuclear-medicine and theranostics departments.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Qualified nuclear-medicine physicians, radiologists, technologists, and other trained healthcare professionals.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.
  • Exact FDA submission
  • Checked 2026-09-03
Evidence summary
Exact-submission testing used a 30-patient held-out evaluation set and reported strong lesion-signal preservation with lower background variability after noise reduction. The evidence is manufacturer generated and must be supplemented with local quantitative and reader acceptance.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
Exact-submission testing used a 30-patient held-out evaluation set and reported strong lesion-signal preservation with lower background variability after noise reduction. The evidence is manufacturer generated and must be supplemented with local quantitative and reader acceptance.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or dose-delivery function. Use the task-specific endpoints and tested population reported below.

Bone lesion-signal correlation

0.99 R-squared

  • EndpointMaximum voxel intensity before versus after noise reduction
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

Bone lesion-signal slope

0.94 slope

  • EndpointMaximum voxel intensity before versus after noise reduction
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

Soft-tissue lesion-signal correlation

0.99 R-squared

  • EndpointMaximum voxel intensity before versus after noise reduction
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

Soft-tissue lesion-signal slope

0.99 slope

  • EndpointMaximum voxel intensity before versus after noise reduction
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

Bone background variability reduction

28 %

  • EndpointReduction in background SD/mean ratio
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

Soft-tissue background variability reduction

20 %

  • EndpointReduction in background SD/mean ratio
  • PopulationVERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001

K254001 FDA performance package for VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

  • DesignManufacturer held-out clinical-image evaluation of lesion-signal preservation and background variability after VERITAS.AI noise reduction
  • Population30 patients: 13 Tc-99m bone studies and 17 soft-tissue studies, including 10 Lu-177 and 7 I-123 MIBG studies
  • Scopeexact submission
  • Tested versionVERITON CT 300/400 Series with optional VERITAS.AI cleared in K254001
  • Samplen=30
  • IndependenceSponsor or vendor study

K254001

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K254001 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: SPECT projection data and CT acquisition data; VERITAS.AI operates on reconstructed SPECT images.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-03 · FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

  2. Routing

    Source context, not route validation: Hybrid SPECT/CT console and DICOM imaging environment; verify quantitative calibration, tracer protocols, workstation routing, and dosimetry round trips.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464) · VERITON Series and VERITAS.AI product-family overview

  3. AI processing

    Source context, not route validation: Installed SPECT/CT system with optional console-integrated VERITAS.AI models.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464) · VERITON Series and VERITAS.AI product-family overview

  4. Returned objects

    Source context, not route validation: SPECT, CT, and fused images plus optional noise-reduced SPECT images and quantitative information.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-03 · FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

  5. Viewer/worklist/report

    Unresolved route: SPECT, CT, and fused images plus optional noise-reduced SPECT images and quantitative information.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-03 · FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Installed SPECT/CT system with optional console-integrated VERITAS.AI models.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Hybrid SPECT/CT console and DICOM imaging environment; verify quantitative calibration, tracer protocols, workstation routing, and dosimetry round trips.
  • Exact FDA submission
  • Checked 2026-09-03
Training
Only qualified nuclear-medicine physicians, radiologists, technologists, and other trained healthcare professionals. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K254001 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Hybrid SPECT/CT console and DICOM imaging environment; verify quantitative calibration, tracer protocols, workstation routing, and dosimetry round trips.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: VERITAS.AI preserves the original reconstruction and is not authorized to change raw data, quantitative values, or dosimetry. Bone-IQ.AI, Thera-IQ.AI, and MIBG-IQ.AI must be used only in their labeled tracer and workflow scopes.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
26Fields reviewed
11Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

Twenty PubMed records and ten trial records were screened. None identifies the VERITON CT 300/400 Series with the K254001 VERITAS.AI release. No evidence was promoted, and all 30 candidates remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision material, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-03 - Exact FDA submission

    Public materials reviewed for this batch do not establish the complete security posture for the exact release. Request data-flow, identity, audit, encryption, retention, support-access, vulnerability-management, backup, and incident-response evidence.

  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K254001: VERITON CT 300 Series Digital SPECT/CT System (VERITON CT 316/364); VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)

    U.S. Food and Drug Administration - Published 2026-01-13 - Accessed 2026-09-04

    Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. VERITON Series and VERITAS.AI product-family overview

    Spectrum Dynamics Medical - Accessed 2026-09-03

    Scope: productFamily, workflowRole, implementationCapabilities, currentCommercialContext

Research history

  1. K254001 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241585

uMI Panorama

Shanghai United Imaging Healthcare Co.,Ltd.

Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation. K241585 adds reconstruction, respiratory-motion, CT-less attenuation-correction, quantitative-normalization, quality-control, and AI-expanded-field-of-view functions.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2024-08-30
FDA-cleared K232712

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-10-03
FDA-cleared K231572

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama GS combines 148 cm axial-field-of-view PET with CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and registered or fused PET/CT images supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation in oncology, cardiology, neurology, inflammation, infection, and other disorders. The CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-07-26
FDA-cleared K223325

uMI Panorama

Shanghai United Imaging Healthcare Co., Ltd.

Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.

Modality
PET/SPECT/Nuclear Medicine
Anatomy
Multi-region
Decision
2023-03-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history